GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » Price-to-Owner-Earnings

NRXBF (NurExone Biologic) Price-to-Owner-Earnings : (As of Apr. 13, 2025)


View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic Price-to-Owner-Earnings?

As of today (2025-04-13), NurExone Biologic's share price is $0.4841. NurExone Biologic does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for NurExone Biologic's Price-to-Owner-Earnings or its related term are showing as below:


NRXBF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 30.005
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-13), NurExone Biologic's share price is $0.4841. NurExone Biologic's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.07. Therefore, NurExone Biologic's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-13), NurExone Biologic's share price is $0.4841. NurExone Biologic's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.07. Therefore, NurExone Biologic's PE Ratio without NRI for today is At Loss.


NurExone Biologic Price-to-Owner-Earnings Historical Data

The historical data trend for NurExone Biologic's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Price-to-Owner-Earnings Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - -

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NurExone Biologic's Price-to-Owner-Earnings

For the Biotechnology subindustry, NurExone Biologic's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Price-to-Owner-Earnings falls into.


;
;

NurExone Biologic Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NurExone Biologic's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.4841/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic  (OTCPK:NRXBF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


NurExone Biologic Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.